The Health Resources and Services Administration (HRSA) intends to launch a 340B Rebate Model Pilot program (Pilot). Under the Pilot, 340B covered entities must request rebates, rather than receive upfront discounts, on drugs sold by 10 participating manufacturers. Beginning January 1, 2027, covered entities purchasing the affected drugs will be required to pay wholesale acquisition cost (WAC) at the time of purchase and then seek reimbursement through a manufacturer-administered rebate process. In practical terms, covered entities will front the full cost of these drugs and then wait to be made whole. This shift creates uncertainty, adds procedural hurdles and increases the risk of cash-flow strain for covered entities that have relied on point-of-sale 340B pricing for over three decades.

On October 9, 2026, the American Hospital Association, together with the Maine Hospital Association and several safety-net hospitals, filed suit in the US District Court for the District of Maine seeking to block HHS and HRSA’s revised 340B rebate pilot before its scheduled January 1, 2027 implementation. The plaintiffs contend that the rebate model, which would replace upfront 340B discounts with a post-purchase rebate process for certain drugs, is arbitrary and capricious under the Administrative Procedure Act because the agencies allegedly failed to adequately consider the program’s substantial administrative costs, cash-flow burdens and operational impacts on covered entities. The lawsuit also seeks emergency injunctive relief and follows earlier litigation in which courts expressed concerns regarding HHS’s analysis of the costs associated with a similar rebate-model proposal.

What is the 340B program?

Congress created the 340B Drug Pricing Program in 1992 to enable safety-net providers “to stretch scarce federal resources as far as possible, reaching more eligible patients and providing more comprehensive services.” Am. Hosp. Ass’n v. Hargan, 289 F. Supp. 3d 45, 47 (D.D.C. 2017) (quoting H.R. Rep. No. 102-384, pt. 2, at 12 (1992)). The program requires drug manufacturers participating in Medicaid and Medicare Part B to sell covered outpatient drugs to eligible providers at a discount. 42 U.S.C. §§ 256b,  1396r-8. For over 30 years, that discount has worked the same way: providers pay the discounted price up front, at the point of sale.

Covered entities are the safety-net providers that Congress designated by statute, including disproportionate share hospitals, federally qualified health centers, critical access hospitals, children’s hospitals and entities that receive grants for outpatient early intervention services for HIV disease or operate State AIDS Drug Assistance Programs (ADAPs). 42 U.S.C. § 256b(a)(4). These entities generally serve vulnerable and underserved populations. Astra USA, Inc. v. Santa Clara Cnty., 563 U.S. 110, 113 (2011).

The US Department of Health and Human Services (HHS) implements the discount through a standard-form Pharmaceutical Pricing Agreement under which each manufacturer commits to charge covered entities no more than a statutory ceiling price, calculated from the drug’s average manufacturer price under Medicaid. 42 U.S.C. § 256b(a)(1)–(2).

The 340B Program already places a significant administrative burden on covered entities. For example, the 340B statute prohibits duplicate discounts by barring covered entities from obtaining a 340B discount on a drug for which a Medicaid drug rebate is also claimed, and it prohibits diversion by barring covered entities from reselling or otherwise transferring a 340B drug to a person who is not a patient of the covered entity. 42 U.S.C. § 256b(a)(5)(A)–(B). Both the HHS Secretary and the manufacturer may audit a covered entity’s records for compliance, but manufacturer audits must follow procedures established by the Secretary. Id. § 256b(a)(5)(C). Under HRSA’s guidelines, a manufacturer must have reasonable cause and submit an audit work plan for HRSA review before auditing. Manufacturer Audit Guidelines and Dispute Resolution Process, 61 Fed. Reg. 65406 (Dec. 12, 1996). If the Secretary finds, after audit and after notice and hearing, that a covered entity violated these prohibitions, the entity is liable to the manufacturer for the amount of the discount. 42 U.S.C.  §256b(a)(5)(D).

In a new issue brief, the HHS Office of the Assistant Secretary for Planning and Evaluation (ASPE) argues that the 340B Drug Pricing Program has expanded substantially beyond its original safety-net purpose and may prioritize the “spread” between the discounted 340B price and the reimbursement covered entities receive over patient needs. ASPE also contends that outsized 340B revenue may encourage consolidation and anticompetitive behavior that increases healthcare costs. Against that backdrop, the brief supports the Centers for Medicare & Medicaid Services’ proposed rule for calendar year 2027 to pay for 340B-acquired drugs at average sales price (ASP) minus 33.4 percent, which ASPE says aims to reflect reported acquisition costs and reduce incentives misaligned with clinical best practices.

History of the HRSA rebate pilot

The 340B Program has operated on an upfront-discount model since its creation in 1992. That model was first challenged in 2024, when several major drug manufacturers began seeking HRSA approval to replace upfront discounts with rebate-based pricing models for certain 340B drugs. HRSA rejected those proposals, and litigation followed. On July 21, 2026, the D.C. Circuit affirmed a district court ruling that Section 340B permits rebate models and that manufacturers may not unilaterally implement them without HHS approval. Novartis Pharms. Corp. v. Kennedy, No. 25-5177 (D.C. Cir. July 21, 2026).

Separately, HRSA announced an initial Rebate Model Pilot Program in August 2025. See 90 Fed. Reg. 36163 (Aug. 1, 2025). On December 29, 2025, the US District Court for the District of Maine preliminarily enjoined that program, which was slated to take effect January 1, 2026. Am. Hosp. Ass’n v. Kennedy, 820 F. Supp. 3d 30 (D. Me. 2025). The First Circuit denied a stay, Am. Hosp. Ass’n v. Kennedy, 164 F.4th 28 (1st Cir. 2026), and HHS then dismissed its appeal and withdrew the program. On February 10, 2026, the District Court vacated the underlying notices and manufacturer approvals and remanded them to HHS. HRSA subsequently revised the Pilot and issued the current version of the program.

HRSA announces rebate pilot

That process culminated in a Federal Register notice on August 3, 2026, announcing the revised Pilot. See Notice Regarding 340B Rebate Model Pilot Program, 91 Fed. Reg. 48883 (Aug. 3, 2026); 340B Rebate Model Pilot Program, Health Res. & Servs. Admin. (last visited Oct. 3, 2026). On October 1, 2026, HRSA announced the manufacturers and drugs approved to participate in the Pilot and released the manufacturers’ final approved implementation plans.

HRSA asserts that rebates improve transparency and program integrity. According to HRSA, the rebate model allows a manufacturer to verify that each claim qualifies for 340B pricing. HRSA contrasted this with the upfront-discount model, which it said provides “limited visibility” into individual transactions, and stated that the rebate model reduces the need for ad hoc reviews and retrospective dispute resolution processes. In addition, HRSA states that a claim-level process supports compliance with the Medicare Drug Price Negotiation Program’s non-duplication provision.

The Pilot applies to drugs on the CMS Medicare Drug Price Negotiation selected drug list for initial price applicability years 2026 and 2027, regardless of payer or indication, during each drug’s price applicability period. According to HRSA, the Pilot is not limited to retail or Part D dispensing and covers these drugs to the extent they are covered outpatient drugs, including physician- or clinic-administered drugs. The Medicare negotiated price and the 340B price are not cumulative: where the 340B ceiling price is lower than the maximum fair price, the manufacturer need not also provide the maximum fair price. 42 U.S.C. § 1320f-2(d).

HRSA approved 21 medications from 10 manufacturers for the Pilot. Covered entities should purchase Pilot drugs through their existing 340B wholesaler accounts with WAC prices loaded and submit rebate claims through the manufacturer’s IT platform.

Both covered entities and manufacturers should maintain auditable records, and HRSA will incorporate rebate-model compliance into its audits of both.

Entity-manufacturer disputes

In the event of a dispute, HRSA has advised that covered entities first contact the manufacturer to attempt a good-faith resolution. If the parties cannot reach an agreement, the covered entity can submit a 340B Rebate Unavailable form to HRSA.

Pilot evaluation

Upon conclusion of the first year of Pilot operations, HRSA will publish an evaluation by April 30, 2028.

What this means for health systems and hospitals

Net price equals the 340B ceiling price

Covered entities will receive rebates equal to WAC minus the 340B ceiling price in effect on the date of dispense, paid at the unit level. This differs from upfront discounts, which are calculated by full package size.

Rebate claim process

Covered entities will submit claims data to the manufacturer’s IT platform within 45 calendar days from the date of dispense. The Pilot provides allowances for extenuating circumstances and other exceptions, though covered entities should not presume these will be broadly available.

Manufacturers have 10 calendar days after a complete claim submission to pay or deny (with documentation) all rebates. If a submission is returned as incomplete, the 10-day clock restarts only when an entity resubmits a claim with all necessary data, so covered entities should build in a buffer rather than assume a full 10 days remain after an incomplete filing.

A manufacturer may not deny a rebate claim based on covered-entity eligibility, diversion or Medicaid duplicate-discount concerns, although it may confirm that the dispensing site is listed in HRSA’s 340B Office of Pharmacy Affairs Information System (OPAIS) when validating a claim. Instead, the manufacturer must raise its concern with HRSA or pursue it through a statutory audit or the 340B administrative dispute resolution process. Other denials require a documented rationale, and rebates may not be denied for a perceived lack of WAC purchases.

Practical challenges for hospitals

The shift from an upfront discount to a rebate model also raises practical burdens beyond the mechanics of implementation. Hospitals have relied on upfront 340B pricing for over 30 years to manage pharmacy budgets and cash flow, and the rebate model requires covered entities to pay full WAC at purchase and wait for a rebate after dispensing.

If rebates are denied or disputed, hospital contract staff should be prepared to negotiate directly with manufacturers and, where necessary, use the good-faith resolution and Rebate Unavailable form process described above.

Hospitals will also face increased administrative burdens under the rebate model. Covered entities and provider organizations have raised concerns over the need for additional staff and related administrative costs. HRSA’s own estimate projects that reporting claims data under the Pilot will result in average administrative costs of approximately US$34,320 per entity annually, though costs may vary by entity type. Covered entities should treat this figure as a floor rather than a ceiling, given the newness of the reporting infrastructure. These additional cash-flow and administrative requirements may present particular challenges for safety-net providers that operate on narrow financial margins.

Moreover, the Pilot may increase covered entities’ audit exposure. Accordingly, hospitals should anticipate additional administrative burdens and plan for the risk of procedural or substantive errors.

Hospitals with significant exposure to the affected drugs should be aware of the risk that delays in receiving rebates or denied claims could reduce the funds available to support patient services, potentially resulting in reduced service capacity or delays in care.

Health systems and hospitals should:

  • Identify:

    • which drugs on their formularies are approved Pilot drugs and
    • which of those drugs are also Medicare-negotiated drugs.
  • Estimate the cash-flow impact of buying Pilot drugs at WAC and carrying that cost through the full purchase-to-payment cycle, which may run up to 45 calendar days for claim submission plus 10 calendar days for manufacturer payment (longer if a claim is returned as incomplete), and reflect those costs in upcoming budgets.

  • Assess whether existing personnel and procedures can:

    • create and submit rebate claims on a transaction basis within 45 calendar days and
    • reconcile rebates received from drug manufacturers.
  • Take note of any accumulations and planned replenishments prior to Pilot implementation on January 1, 2027.

    • Covered entities may request rebates for up to 2 unreplenished accumulated packages dispensed during the 15 calendar days before January 1, 2027 (for example, a package dispensed on December 16). Those requests must still be submitted within 45 days of dispense.
    • Accumulations outside this limited accommodation should be resolved before January 1, 2027. Covered entities should review each manufacturer’s approved plan, as some plans apply the two-package limit per 11-digit National Drug Code (NDC), exclude packages already replenished through a 340B chargeback, or impose other conditions.

Contact